CYTK: Cytokinetics Inc Company Value to Net Income

The P/E valuation trend on the GURU.Markets chart confirms growing demand for innovative cardiovascular drugs, while -9.70 represents the current value of this metric. The business model is based on R&D expenditures with the potential for a sharp increase in profit following FDA approval. However, the stability of Cytokinetics (CYTK) depends on test results and the availability of capital for commercialization.

Cytokinetics Inc - CYTK P/E Multiple (period 07/04/2022 - 11/10/2026)

Analytical breakdowns for Cytokinetics

- price and consensus price forecast:

Stock Price cytokinetics.com|CYTK - Consensus Target

- market capitalization information:

Market Value Cytokinetics, Incorporated|CYTK - Total Company Value

- balance sheet net asset value indicators:

Equity per Share Cytokinetics|CYTK - Book Capitalization|Market-to-Book Ratio cytokinetics.com|CYTK - Cumulative Company Assets

- company liabilities and liquidity data:

- financial results and valuation multiples details:

CYTK - Net Profit|Projected Net Profit Cytokinetics|CYTK - Price to Earnings Ratio|Projected Price to Earnings Ratio Cytokinetics Inc.|CYTK - PEG Multiple|Enterprise Value to EBITDA Ratio Cytokinetics, Incorporated|CYTK - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Cytokinetics|CYTK - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months cytokinetics.com|CYTK - Earnings per share growth in current year|Expected net earnings per share growth next year Cytokinetics

Comprehensive company analysis:CYTK (cytokinetics.com)

Investments in Cytokinetics (CYTK) rely on the success of muscle biology scientists, whose clinical achievements directly determine the market value of the shares. The price-to-earnings ratio measures the payback period of capital, reflecting the market's willingness to reward future growth, which allows for the differentiation of the issuer's fundamental stability from short-term speculative movements amid credit tightening through the company's P/E fluctuations.

Analysis of competing companies